Activating GNAS oncogene mutation in the fluid of the dilated MPD using DNA-based NGS is a promising biomarker for distinguishing MD-IPMN from CP and is more frequently detectable in MD-IPMN than in fish-mouth papilla. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.